Different exploratory efficacy endpoints have been studied in clinical trials in patients with NASH cirrhosis, including changes in liver biochemistry tests; non‐invasive tests (eg enhanced liver fibrosis [ELF], liver stiffness by transient elastography); markers of apoptosis and necrosis and other histological measures including hepatic collagen and fat content and α‐SMA expression.32, 61. The gene discussed is ACTA1; the disease is metabolic dysfunction-associated steatohepatitis.